316 related articles for article (PubMed ID: 25202923)
41. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
[TBL] [Abstract][Full Text] [Related]
42. A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity.
Ross TM; Pereira LE; Luckay A; McNicholl JM; García-Lerma JG; Heneine W; Eugene HS; Pierce-Paul BR; Zhang J; Hendry RM; Smith JM
AIDS Res Hum Retroviruses; 2014 Nov; 30(11):1072-81. PubMed ID: 24914761
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
[TBL] [Abstract][Full Text] [Related]
44. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
Valantin MA; Bittar R; de Truchis P; Bollens D; Slama L; Giral P; Bonnefont-Rousselot D; Pétour P; Aubron-Olivier C; Costagliola D; Katlama C;
J Antimicrob Chemother; 2010 Mar; 65(3):556-61. PubMed ID: 20053692
[TBL] [Abstract][Full Text] [Related]
45. Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
Gazzard BG
Expert Opin Pharmacother; 2006 Apr; 7(6):793-802. PubMed ID: 16556093
[TBL] [Abstract][Full Text] [Related]
46. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
47. Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques.
Kersh EN; Luo W; Adams DR; Mitchell J; Garcia-Lerma JG; Heneine W; Folks TM; Butera S; Otten RA
AIDS Res Hum Retroviruses; 2008 Apr; 24(4):543-6. PubMed ID: 18370590
[TBL] [Abstract][Full Text] [Related]
48. When is good good enough for HIV-1 prophylaxis?
Buchbinder S
Lancet Infect Dis; 2014 Nov; 14(11):1024-1025. PubMed ID: 25300861
[No Abstract] [Full Text] [Related]
49. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
van de Vijver DA; Boucher CA
Curr Opin Infect Dis; 2010 Dec; 23(6):621-7. PubMed ID: 20847692
[TBL] [Abstract][Full Text] [Related]
50. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
51. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
Rockstroh JK; DeJesus E; Lennox JL; Yazdanpanah Y; Saag MS; Wan H; Rodgers AJ; Walker ML; Miller M; DiNubile MJ; Nguyen BY; Teppler H; Leavitt R; Sklar P;
J Acquir Immune Defic Syndr; 2013 May; 63(1):77-85. PubMed ID: 23412015
[TBL] [Abstract][Full Text] [Related]
52. Double oral administration of emtricitabine/tenofovir prior to virus exposure protects against highly pathogenic simian/human immunodeficiency virus infection in macaques.
Nakasone T; Murakami T; Yamamoto N
Jpn J Infect Dis; 2012 Jul; 65(4):345-9. PubMed ID: 22814162
[TBL] [Abstract][Full Text] [Related]
53. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
[TBL] [Abstract][Full Text] [Related]
54. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
55. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
[TBL] [Abstract][Full Text] [Related]
56. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
Marcus JL; Glidden DV; Mayer KH; Liu AY; Buchbinder SP; Amico KR; McMahan V; Kallas EG; Montoya-Herrera O; Pilotto J; Grant RM
PLoS One; 2013; 8(12):e81997. PubMed ID: 24367497
[TBL] [Abstract][Full Text] [Related]
57. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Orkin C; DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Vandercam B; de Wet J; Rockstroh J; Lazzarin A; Rijnders B; Podzamczer D; Thalme A; Stoeckle M; Porter D; Liu HC; Cheng A; Quirk E; SenGupta D; Cao H
Lancet HIV; 2017 May; 4(5):e195-e204. PubMed ID: 28259777
[TBL] [Abstract][Full Text] [Related]
58. Ethics and pre-exposure prophylaxis for HIV infection.
Sugarman J; Mayer KH
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S135-9. PubMed ID: 23764625
[TBL] [Abstract][Full Text] [Related]
59. Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
Clercq ED
Biochem Pharmacol; 2012 Mar; 83(5):567-73. PubMed ID: 22067069
[TBL] [Abstract][Full Text] [Related]
60. FDA paves the way for pre-exposure HIV prophylaxis.
Holmes D
Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]